MeiraGTx names Alan Sebulsky to its board of directors

MeiraGTx Holdings plc (NASDAQ: MGTX) has appointed Alan M. Sebulsky to its board of directors, the clinical-stage genetic medicines company announced.

Sebulsky brings more than 40 years of experience in public company investment, financial strategy, and portfolio management. He most recently served as partner and portfolio manager at Adage Capital Management for 14 years, where he oversaw a biopharmaceutical portfolio with over $2 billion in assets.

Sebulsky founded Apothecary Capital, an asset management firm focused on healthcare and biopharmaceutical investments, and reestablished the firm in April 2026, where he currently serves as managing member.

He currently serves on the board of Parabilis Medicines, Inc. and previously held board and audit committee positions at Jazz Pharmaceuticals and Arrow International, both publicly traded healthcare companies. He also served on the boards of three private healthcare companies.

Alexandria Forbes, president and chief executive officer of MeiraGTx, said Sebulsky's "decades of investing in and working with biopharmaceutical companies brings a valuable perspective to the board which is particularly important as we continue to transform MeiraGTx into a commercial company."

Sebulsky holds an M.S. in finance and a B.B.A. in finance and economics from the University of Wisconsin–Madison.

You May Also Be Interested In

• MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors
• VICI Properties adds former Cadillac Fairview CEO to its board
• NioBay Metals names Rio Tinto veteran to its board of directors